Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
V129241-1g | 1g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $49.90 | |
V129241-5g | 5g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $164.90 | |
V129241-25g | 25g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $739.90 | |
V129241-100g | 100g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $2,662.90 |
Highly selective, potent, competitive AT 1 receptor antagonist
Synonyms | HSDB 7519 | Valsartan [USAN:USP:INN:BAN] | 80M03YXJ7I | Tareg | VALSARTAN (USP-RS) | MLS001424088 | VALSARTAN [INN] | ENTRESTO COMPONENT VALSARTAN | Spectrum_001796 | Miten | VALSARTAN [MART.] | VALSARTAN [VANDF] | VALSARTAN [EMA EPAR] | VALSARTAN [HSDB] |
---|---|
Specifications & Purity | Moligand™, ≥98%(HPLC) |
Biochemical and Physiological Mechanisms | Valsartan is a nonpeptide AT1 (angiotensin II AT1-receptor) antagonist with an IC50 ranging from 39.5 to 116 μM. This in turn causes blood vessel dilation.Highly selective, potent, competitive AT 1 receptor antagonist (K i = 2.38 nM). Shows antihypertensi |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of AT 1 receptor |
Note | Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Valsartan is an angiotensin II receptor antagonist with IC50 of ranging from 39.5 to 116 μM. Valsartan is an orally active specific angiotensin II receptor blocker used for the treatment of hypertension |
ALogP | 4.4 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid |
---|---|
INCHI | InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1 |
InChi Key | ACWBQPMHZXGDFX-QFIPXVFZSA-N |
Canonical SMILES | CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O |
Isomeric SMILES | CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O |
WGK Germany | 3 |
Alternate CAS | 137862-53-4 |
PubChem CID | 60846 |
NSC Number | 758927 |
MeSH Entry Terms | 48933, CGP;CGP 48933;Diovan;Kalpress;Miten;N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine;Nisis;Provas;Tareg;Vals;valsartan |
Molecular Weight | 435.52 |
DrugBank Ligand | DB00177 |
---|---|
Wikipedia | Valsartan |
ChEBI | CHEBI:9927 |
CAS Registry No. | 137862-53-4 |
PubChem CID | 60846 |
ChEMBL Ligand | CHEMBL1069 |
PEP | valsartan |
Reactome Reaction | R-HSA-9615249 |
Reactome Drug | R-ALL-9615299 |
DrugCentral Ligand | 2806 |
RCSB PDB Ligand | U35 |
GPCRdb Ligand | valsartan |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
K2127016 | Certificate of Analysis | Sep 20, 2023 | V129241 |
K2127017 | Certificate of Analysis | Sep 20, 2023 | V129241 |
E1526061 | Certificate of Analysis | Jan 16, 2023 | V129241 |
B2318250 | Certificate of Analysis | Jan 05, 2023 | V129241 |
B2318251 | Certificate of Analysis | Jan 05, 2023 | V129241 |
B2318252 | Certificate of Analysis | Jan 05, 2023 | V129241 |
H2407057 | Certificate of Analysis | Jan 05, 2023 | V129241 |
J2418270 | Certificate of Analysis | Jan 05, 2023 | V129241 |
G2216548 | Certificate of Analysis | Jun 10, 2022 | V129241 |
E2027052 | Certificate of Analysis | Apr 25, 2022 | V129241 |
Solubility | Soluble in Ethanol and Methanol |
---|---|
Sensitivity | Moisture sensitive |
Specific Rotation[α] | -65°C |
Melt Point(°C) | 117°C |
Pictogram(s) | GHS08 |
---|---|
Signal | Warning |
Hazard Statements | H412:Harmful to aquatic life with long lasting effects H361:Suspected of damaging fertility or the unborn child |
Precautionary Statements | P273:Avoid release to the environment. P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. |
WGK Germany | 3 |
Merck Index | 9916 |
Starting at $459.90
Starting at $332.90
Starting at $390.90
Starting at $237.90
Starting at $332.90
Starting at $9.90
Starting at $99.90
Starting at $59.90
Starting at $138.90
Starting at $285.90
Starting at $285.90
Starting at $142.90
1. Qinglin Wang, Hao Yuan, Xinyue Pan, Yiling Yang, Xiaosong Ma, Yahui Guo. (2024) Synthesis of silver nanoclusters using a double-stranded DNA template and its application for captopril detection. JOURNAL OF FOOD COMPOSITION AND ANALYSIS, 126 (17): (105825). [PMID:17580304] [10.1016/j.jfca.2023.105825] |
2. Huimin Zhou, Zhiwei Qiu, Jin Zeng, Ruobin Dai, Zhiwei Wang. (2023) Ultra-permeable polyamide nanofiltration membrane modified by hydrophilic-hydrophobic alternated lignocellulosic nanofibrils for efficient water reuse. JOURNAL OF MEMBRANE SCIENCE, 688 (15): (122125). [PMID:10677542] [10.1016/j.memsci.2023.122125] |
3. Zhiren Zou, Qiang Huang, Xiaobo Li, Xianzhi Liu, Lina Yin, Yunjie Zhao, Guang Liang, Wenqi Wu. (2023) Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 188 (106526). [PMID:37442486] [10.1016/j.ejps.2023.106526] |
4. Mingkang Zhang, Ruirui Cui, Yan Zhou, Yanrong Ma, Yongwen Jin, Lina Wang, Wen Kou, Xin’an Wu. (2023) Accumulation of Renal Fibrosis in Hyperuricemia Rats Is Attributed to the Recruitment of Mast Cells, Activation of the TGF-β1/Smad2/3 Pathway, and Aggravation of Oxidative Stress. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (13): (10839). [PMID:37446016] [10.3390/ijms241310839] |
5. Yupeng Shi, Mengyang Zhou, Shuo Zhao, Haotian Li, Wenhao Wang, Jingliang Cheng, Lin Jin, Yifei Wang. (2023) Janus amphiphilic nanofiber membranes synergistically drive antibacterial and anti-inflammatory strategies for skin wound healing. MATERIALS & DESIGN, 227 (111778). [PMID:] [10.1016/j.matdes.2023.111778] |
6. Qiang Huang, Zhiren Zou, Xiaobo Li, Qinwen Xiao, Guang Liang, Wenqi Wu. (2023) Poly (amino acid)s as new co-formers in amorphous solid dispersion. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 634 (122645). [PMID:36706970] [10.1016/j.ijpharm.2023.122645] |
7. Mingkang Zhang, Ruirui Cui, Yan Zhou, Yanrong Ma, Yongwen Jin, Xueyan Gou, Jinru Yang, Xin’an Wu. (2023) Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. TOXICOLOGY, 483 (153387). [PMID:36464070] [10.1016/j.tox.2022.153387] |
8. Lin Chen, Li Ge, Qinghui Liang, Zhenbo Zhao, Kedi Yang. (2022) Eutectic solvents formed by (+)-DTTA and L-menthol as novel chiral recognition and separation media for enantioselective extraction of valsartan enantiomers. JOURNAL OF MOLECULAR LIQUIDS, 368 (120818). [PMID:] [10.1016/j.molliq.2022.120818] |
9. Ke Lin, Wu Luo, Na Yang, Lan Su, Hao Zhou, Xiang Hu, Yi Wang, Zia A. Khan, Weijian Huang, Gaojun Wu, Guang Liang. (2022) Inhibition of MyD88 attenuates angiotensin II-induced hypertensive kidney disease via regulating renal inflammation. INTERNATIONAL IMMUNOPHARMACOLOGY, 112 (109218). [PMID:36116148] [10.1016/j.intimp.2022.109218] |
10. Wang Yiran, Shi Jihua, Dai Dapeng, Cai Jianping, Wang Shuanghu, Hong Yun, Zhou Shan, Zhao Fangling, Zhou Quan, Geng Peiwu, Zhou Yunfang, Xu Xue, Luo Qingfeng. (2022) Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo. Frontiers in Pharmacology, 13 [PMID:36052128] [10.3389/fphar.2022.909168] |
11. Yan Zhou, Mengmeng Wei, Mingkang Zhang, Jianping Zhang, Fabing Tang, Xin’an Wu. (2022) Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis. TOXICOLOGY LETTERS, 359 (10). [PMID:35114312] [10.1016/j.toxlet.2022.01.018] |
12. Xiao Juan Liu, Yang Zhang, Xue Zhong Wang. (2020) Study on Co-Crystallization of LCZ696 Using In Situ ATR-FTIR and Imaging. Crystals, 10 (10): (922). [PMID:] [10.3390/cryst10100922] |
13. Qi Liang, Xiaoying Fu, Jianfeng Zhang, Jiaxue Hao, Gangjun Feng, Jing Wang, Qian Li, Faizan Ahmad, Xinfeng Zhao. (2020) Immobilized angiotensin II type I receptor: A powerful method of high throughput screening for antihypertensive compound identification through binding interaction analysis. JOURNAL OF CHROMATOGRAPHY A, 1620 (461003). [PMID:32156458] [10.1016/j.chroma.2020.461003] |
14. Yi-Lin Sun, Peng-Hui Li, Ling Shi, Wan-Zhen Su, De-Sheng Li, Gen-Long Xue, Yue Zhao, Chang-Zhu Li, Ying Li, Yang Zhou, Shang-Xuan Li, Yang Zhang, Yan-Jie Lu, Zhen-Wei Pan. (2018) Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 29 (10): (1436-1443). [PMID:30016000] [10.1111/jce.13697] |
1. Qinglin Wang, Hao Yuan, Xinyue Pan, Yiling Yang, Xiaosong Ma, Yahui Guo. (2024) Synthesis of silver nanoclusters using a double-stranded DNA template and its application for captopril detection. JOURNAL OF FOOD COMPOSITION AND ANALYSIS, 126 (17): (105825). [PMID:17580304] [10.1016/j.jfca.2023.105825] |
2. Huimin Zhou, Zhiwei Qiu, Jin Zeng, Ruobin Dai, Zhiwei Wang. (2023) Ultra-permeable polyamide nanofiltration membrane modified by hydrophilic-hydrophobic alternated lignocellulosic nanofibrils for efficient water reuse. JOURNAL OF MEMBRANE SCIENCE, 688 (15): (122125). [PMID:10677542] [10.1016/j.memsci.2023.122125] |
3. Zhiren Zou, Qiang Huang, Xiaobo Li, Xianzhi Liu, Lina Yin, Yunjie Zhao, Guang Liang, Wenqi Wu. (2023) Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 188 (106526). [PMID:37442486] [10.1016/j.ejps.2023.106526] |
4. Mingkang Zhang, Ruirui Cui, Yan Zhou, Yanrong Ma, Yongwen Jin, Lina Wang, Wen Kou, Xin’an Wu. (2023) Accumulation of Renal Fibrosis in Hyperuricemia Rats Is Attributed to the Recruitment of Mast Cells, Activation of the TGF-β1/Smad2/3 Pathway, and Aggravation of Oxidative Stress. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (13): (10839). [PMID:37446016] [10.3390/ijms241310839] |
5. Yupeng Shi, Mengyang Zhou, Shuo Zhao, Haotian Li, Wenhao Wang, Jingliang Cheng, Lin Jin, Yifei Wang. (2023) Janus amphiphilic nanofiber membranes synergistically drive antibacterial and anti-inflammatory strategies for skin wound healing. MATERIALS & DESIGN, 227 (111778). [PMID:] [10.1016/j.matdes.2023.111778] |
6. Qiang Huang, Zhiren Zou, Xiaobo Li, Qinwen Xiao, Guang Liang, Wenqi Wu. (2023) Poly (amino acid)s as new co-formers in amorphous solid dispersion. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 634 (122645). [PMID:36706970] [10.1016/j.ijpharm.2023.122645] |
7. Mingkang Zhang, Ruirui Cui, Yan Zhou, Yanrong Ma, Yongwen Jin, Xueyan Gou, Jinru Yang, Xin’an Wu. (2023) Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. TOXICOLOGY, 483 (153387). [PMID:36464070] [10.1016/j.tox.2022.153387] |
8. Lin Chen, Li Ge, Qinghui Liang, Zhenbo Zhao, Kedi Yang. (2022) Eutectic solvents formed by (+)-DTTA and L-menthol as novel chiral recognition and separation media for enantioselective extraction of valsartan enantiomers. JOURNAL OF MOLECULAR LIQUIDS, 368 (120818). [PMID:] [10.1016/j.molliq.2022.120818] |
9. Ke Lin, Wu Luo, Na Yang, Lan Su, Hao Zhou, Xiang Hu, Yi Wang, Zia A. Khan, Weijian Huang, Gaojun Wu, Guang Liang. (2022) Inhibition of MyD88 attenuates angiotensin II-induced hypertensive kidney disease via regulating renal inflammation. INTERNATIONAL IMMUNOPHARMACOLOGY, 112 (109218). [PMID:36116148] [10.1016/j.intimp.2022.109218] |
10. Wang Yiran, Shi Jihua, Dai Dapeng, Cai Jianping, Wang Shuanghu, Hong Yun, Zhou Shan, Zhao Fangling, Zhou Quan, Geng Peiwu, Zhou Yunfang, Xu Xue, Luo Qingfeng. (2022) Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo. Frontiers in Pharmacology, 13 [PMID:36052128] [10.3389/fphar.2022.909168] |
11. Yan Zhou, Mengmeng Wei, Mingkang Zhang, Jianping Zhang, Fabing Tang, Xin’an Wu. (2022) Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis. TOXICOLOGY LETTERS, 359 (10). [PMID:35114312] [10.1016/j.toxlet.2022.01.018] |
12. Xiao Juan Liu, Yang Zhang, Xue Zhong Wang. (2020) Study on Co-Crystallization of LCZ696 Using In Situ ATR-FTIR and Imaging. Crystals, 10 (10): (922). [PMID:] [10.3390/cryst10100922] |
13. Qi Liang, Xiaoying Fu, Jianfeng Zhang, Jiaxue Hao, Gangjun Feng, Jing Wang, Qian Li, Faizan Ahmad, Xinfeng Zhao. (2020) Immobilized angiotensin II type I receptor: A powerful method of high throughput screening for antihypertensive compound identification through binding interaction analysis. JOURNAL OF CHROMATOGRAPHY A, 1620 (461003). [PMID:32156458] [10.1016/j.chroma.2020.461003] |
14. Yi-Lin Sun, Peng-Hui Li, Ling Shi, Wan-Zhen Su, De-Sheng Li, Gen-Long Xue, Yue Zhao, Chang-Zhu Li, Ying Li, Yang Zhou, Shang-Xuan Li, Yang Zhang, Yan-Jie Lu, Zhen-Wei Pan. (2018) Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 29 (10): (1436-1443). [PMID:30016000] [10.1111/jce.13697] |